10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds

3. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 29

Average Upside: 46.28%

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology, developing groundbreaking treatments for serious diseases using its proprietary gene sequencing platform, enabling precise DNA modifications.

The company’s launch of Casgevy and its growing pipeline have garnered considerable interest from investors and analysts. Currently, more than 35 Authorized Treatment Centers (ATCs) have been activated worldwide, representing a notable increase from previous quarters.

Needham adjusted its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) back in August, lowering it from $88 to $84 while maintaining a Buy rating. The revision followed the company’s report of no Casgevy sales in Q2 2024. Despite this, the biotech company seems to have made progress, with around 20 patients undergoing cell collection for treatment, signaling active patient engagement.

Insider Monkey’s Q2 2024 data shows that 29 of the 912 hedge funds tracked held positions in CRISPR Therapeutics AG (NASDAQ:CRSP). Cathie Wood’s ARK Investment Management was the largest shareholder, with holdings valued at $420.1 million.